1
|
Klein E, Beckert V, Schmidt G, Kiechle M, Paepke S. Use of Arista™ AH Absorbable Hemostat in breast surgery – analysis of seroma volumes and duration of drainage. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01381-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
2
|
Munawwar B, Klein E, Schmidt G, Rief L, Heinemann F, Kiechle M, Paepke S. Comparison of Technetium (Tc)- and SPIO-guided Sentinel Lymph Node Biopsy (SLNB) in Patients with Neoadjuvant Chemotherapy in Early Breast Cancer – first retrospective data. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01380-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
3
|
Schrodi S, Braun M, Andrulat A, Harbeck N, Mahner S, Kiechle M, Klein E, Schnelzer A, Schindlbeck C, Bauerfeind I, Schubert-Fritschle G, Nekljudova V, Mayr D, Weichert W, Denkert C, Loibl S, Engel J. Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort. Ann Oncol 2021; 32:1410-1424. [PMID: 34419555 DOI: 10.1016/j.annonc.2021.08.1988] [Citation(s) in RCA: 30] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2021] [Revised: 07/08/2021] [Accepted: 08/10/2021] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Guideline recommendations for the treatment of breast cancer with low hormone receptor (HR) expression (1%-9%) are ambiguous and several studies showed more similarities with HR-negative tumors than with HR strongly positive tumors (≥10%). We used a population-based 15-year cohort to compare patient characteristics and outcome of HR low positive tumors with HR-negative and HR strongly positive tumors, respectively. PATIENTS AND METHODS A total of 38 560 women diagnosed with early invasive breast cancer between 2004 and 2018 within the scope of the Munich Cancer Registry with 4.9 million inhabitants were included. Descriptive analyses of prognostic factors, treatment, and outcome analyses using the Kaplan-Meier method; cumulative incidence in consideration of competing risks; and multivariate analyses (Cox regression and Fine-Gray model) were conducted. Endpoints were time to local recurrence (TTLR), time to lymph node recurrence (TTLNR), time to metastasis (TTM), overall survival (OS), and relative survival (RS). RESULTS A total of 861 patients (2%) had HR low positive, 4862 (13%) HR-negative, and 32 837 (85%) HR strongly positive tumors. Within the HER2-negative cohort (n = 33 366), survival of HR low positive tumors was significantly worse than that of HR strongly positive tumors [OS hazard ratio 0.66 (95% confidence interval 0.55-0.78)], whereas between HR low positive and HR-negative tumors no significant survival difference could be detected [OS hazard ratio 0.93 (95% confidence interval 0.78-1.11)]. TTLR, TTLNR, and TTM showed similar results. By contrast, within the HER2-positive cohort (n = 5194), no statistically significant differences between the three HR groups could be detected in multivariate analyses. CONCLUSION Current definitions for HR positivity and its clinical relevance should be reconsidered. Patients with HR low positive/HER2-negative tumors could be regarded and treated similar to patients with triple-negative tumors.
Collapse
Affiliation(s)
- S Schrodi
- Munich Cancer Registry (MCR) at the Institute of Medical Information Processing, Biometry, and Epidemiology (IBE), Ludwig-Maximilians-University (LMU), Bavarian Cancer Registry - Regional Centre Munich, Bavarian Health and Food Safety Authority (LGL), Munich, Germany.
| | - M Braun
- Department of Gynecology and Obstetrics, Breast Centre, Red Cross Hospital, Munich, Germany
| | - A Andrulat
- Department of Gynecology and Obstetrics, Breast Centre, Red Cross Hospital, Munich, Germany
| | - N Harbeck
- Department of Obstetrics and Gynecology and Breast Centre, University Hospital, Ludwig-Maximilians-University Munich (LMU), Munich, Germany
| | - S Mahner
- Department of Obstetrics and Gynecology and Breast Centre, University Hospital, Ludwig-Maximilians-University Munich (LMU), Munich, Germany
| | - M Kiechle
- Department of Gynecology and Obstetrics, Breast Centre, University Hospital, Technical University Munich (TUM), Munich, Germany
| | - E Klein
- Department of Gynecology and Obstetrics, Breast Centre, University Hospital, Technical University Munich (TUM), Munich, Germany
| | - A Schnelzer
- Department of Obstetrics and Gynecology, Breast Centre, RoMed Kliniken, Rosenheim, Germany
| | - C Schindlbeck
- Department of Obstetrics and Gynecology and Breast Centre, University Hospital, Ludwig-Maximilians-University Munich (LMU), Munich, Germany; Department of Gynecology and Obstetrics, Breast Centre, Klinikum Traunstein, Traunstein, Germany
| | - I Bauerfeind
- Department of Gynecology and Obstetrics, Breast Centre, Klinikum Landshut, Landshut, Germany
| | - G Schubert-Fritschle
- Munich Cancer Registry (MCR) at the Institute of Medical Information Processing, Biometry, and Epidemiology (IBE), Ludwig-Maximilians-University (LMU), Bavarian Cancer Registry - Regional Centre Munich, Bavarian Health and Food Safety Authority (LGL), Munich, Germany
| | - V Nekljudova
- German Breast Group (GBG Forschungs GmbH), Neu-Isenburg, Germany
| | - D Mayr
- Department of Pathology, Ludwig-Maximilians-University (LMU), Munich, Germany
| | - W Weichert
- Institute of Pathology, Technical University Munich (TUM), Munich, Germany
| | - C Denkert
- Department of Pathology, University Hospital Marburg (UKGM), Philipps-University Marburg, Marburg, Germany
| | - S Loibl
- German Breast Group (GBG Forschungs GmbH), Neu-Isenburg, Germany; Centre for Haematology and Oncology Bethanien, Frankfurt, Germany
| | - J Engel
- Munich Cancer Registry (MCR) at the Institute of Medical Information Processing, Biometry, and Epidemiology (IBE), Ludwig-Maximilians-University (LMU), Bavarian Cancer Registry - Regional Centre Munich, Bavarian Health and Food Safety Authority (LGL), Munich, Germany
| |
Collapse
|
4
|
Noske A, Wagner DC, Schwamborn K, Foersch S, Steiger K, Kiechle M, Karapetyan S, Oettler D, Hapfelmeier A, Roth W, Weichert W. 13P Comparison study of different programmed death-ligand 1 (PD-L1) assays, readers and scoring methods in triple-negative breast cancer (TNBC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.03.027] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
5
|
Grimm D, Paepke D, Voiss P, Cramer H, Kuemmel S, Beckmann M, Kalder M, Wölber L, Kiechle M, Schmalfeldt B, Hasenburg A, Hack C. Gynecologists´ attitude towards their use of complementary and integrative medicine approaches: results of a nationwide AGO IMed survey. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- D. Grimm
- Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, University of Luebeck
| | - D. Paepke
- Department of Gynecology, Technische Universitaet Muenchen
| | - P. Voiss
- Department of Internal and Integrative Medicine, Kliniken Essen-Mitte
| | - H. Cramer
- Department of Internal and Integrative Medicine, Kliniken Essen-Mitte
| | - S. Kuemmel
- Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuernberg, Comprehensive Cancer Center Erlangen-EMN
| | - M. Beckmann
- Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuernberg, Comprehensive Cancer Center Erlangen-EMN
| | - M. Kalder
- Department of Gynecology and Obstetrics, Philipps University of Marburg
| | - L. Wölber
- Department of Gynaecology and Gynaecologic Oncology, University Medical Center Hamburg-Eppendorf
| | - M. Kiechle
- Department of Gynaecology, Technische Universitaet Muenchen
| | | | - A. Hasenburg
- Department of Obstetrics and Gynecology, University Medical Center
| | - C. Hack
- Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuernberg, Comprehensive Cancer Center Erlangen-EMN
| |
Collapse
|
6
|
Paepke S, Kiechle M, Gerber-Schäfer C, Kümmel S, Faridi A, Bauer L, Thill M, Ankel C, Andrulat A, Gschwantler-Kaulich D, Heil J, Fink V, Ohlinger R. Präpektorale Implantateinlage in der plastisch-rekonstruktiven Mammachirurgie unter Verwendung des TiLOOP Bra Pocket – erste Daten der PRO-Pocket Studie. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717892] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- S Paepke
- Klinikum rechts der Isar,pechnische Universität München
| | - M Kiechle
- Klinikum rechts der Isar,pechnische Universität München
| | | | | | | | | | - M Thill
- Agaplesion Markus Krankenhaus
| | | | | | | | - J Heil
- Universitätsklinikum Heidelberg
| | | | | |
Collapse
|
7
|
Seitz S, Stange C, Dreyer T, Nikonov J, Kiechle M, Bronger H. Der PARP-Inhibitor Olaparib induziert die tumor-suppressiven Chemokine CXCL9 und CX3CL1 im Ovarialkarzinom. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- S Seitz
- Frauenklinik und Poliklinik der Technischen Universität München (TUM)
| | - C Stange
- Frauenklinik und Poliklinik der Technischen Universität München (TUM)
| | - T Dreyer
- Frauenklinik und Poliklinik der Technischen Universität München (TUM)
| | - J Nikonov
- Frauenklinik und Poliklinik der Technischen Universität München (TUM)
| | - M Kiechle
- Frauenklinik und Poliklinik der Technischen Universität München (TUM)
| | - H Bronger
- Frauenklinik und Poliklinik der Technischen Universität München (TUM)
| |
Collapse
|
8
|
Stange C, Dreyer T, Seitz S, Nikonov J, Kiechle M, Bronger H. Die Dipeptidylpeptidase 4 (DPP4) ist eine neue Zielstruktur zur Verbesserung einer Olaparib-Therapie im Ovarialkarzinom. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- C Stange
- Frauenklinik und Poliklinik der Technischen Universität München (TUM)
| | - T Dreyer
- Frauenklinik und Poliklinik der Technischen Universität München (TUM)
| | - S Seitz
- Frauenklinik und Poliklinik der Technischen Universität München (TUM)
| | - J Nikonov
- Frauenklinik und Poliklinik der Technischen Universität München (TUM)
| | - M Kiechle
- Frauenklinik und Poliklinik der Technischen Universität München (TUM)
| | - H Bronger
- Frauenklinik und Poliklinik der Technischen Universität München (TUM)
| |
Collapse
|
9
|
Paepke S, Kiechle M, Karsten M, Blohmer J, Schmidt G, Stassek J, Kühn T, Thill M. SPIO-guided Sentinel Lymph Node Biopsy (SLNB) in early Breast Cancer – first monoinstitutional data and perspectives. Eur J Cancer 2020. [DOI: 10.1016/s0959-8049(20)30590-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
10
|
Rudolph K, CE B, Kiechle M, Nest A, Pichler T, Paepke D. Auswertung des FBK-R10 Fragebogens zur aktuellen Belastung und zum Wunsch nach psychoonkologischer Unterstützung bei Patientinnen mit gynäkologischen Tumorerkrankungen. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- K Rudolph
- Frauenklinik und Poliklinik der Technischen Universität München (TUM)
| | - Brambs CE
- Frauenklinik und Poliklinik der Technischen Universität München (TUM)
| | - M Kiechle
- Frauenklinik und Poliklinik der Technischen Universität München (TUM)
- Comprehensive Cancer Center der Technischen Universität München (CCCM-TUM)
| | - A Nest
- Comprehensive Cancer Center der Technischen Universität München (CCCM-TUM)
| | - T Pichler
- Comprehensive Cancer Center der Technischen Universität München (CCCM-TUM)
| | - D Paepke
- Frauenklinik und Poliklinik der Technischen Universität München (TUM)
| |
Collapse
|
11
|
Jansen H, Große Lackmann K, Wilhelm M, Lorinser V, Dempf A, Schallehn M, Kiechle M. Prospektiv randomisierte, multizentrische Studie zur Untersuchung des Einflusses einer webbasierten Softwareapplikation (App) auf die Therapietreue und Lebensqualität bei Frauen mit einem primären Mammakarzinom/Duktalen Carcinoma in situ (DCIS). Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- H Jansen
- Klinikum rechts der Isar der Technischen Universität München, Gynäkologie
| | - K Große Lackmann
- Klinikum rechts der Isar der Technischen Universität München, Gynäkologie
| | | | | | - A Dempf
- Telum GmbH, Business IT Solutions
| | | | - M Kiechle
- Klinikum rechts der Isar der Technischen Universität München, Gynäkologie
| |
Collapse
|
12
|
Magno G, Dreyer T, Käfinger K, Gong W, Dorn J, Kiechle M, Magdolen V, Bronger H. Die Kallikrein-ähnliche Peptidase KLK7 als neue Zielstruktur zur Verbesserung der Immuntherapie im Ovarialkarzinom. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- G Magno
- Frauenklinik und Poliklinik der Technischen Universität München (TUM)
| | - T Dreyer
- Frauenklinik und Poliklinik der Technischen Universität München (TUM)
| | - K Käfinger
- Frauenklinik und Poliklinik der Technischen Universität München (TUM)
| | - W Gong
- Frauenklinik und Poliklinik der Technischen Universität München (TUM)
| | - J Dorn
- Frauenklinik und Poliklinik der Technischen Universität München (TUM)
| | - M Kiechle
- Frauenklinik und Poliklinik der Technischen Universität München (TUM)
| | - V Magdolen
- Frauenklinik und Poliklinik der Technischen Universität München (TUM)
| | - H Bronger
- Frauenklinik und Poliklinik der Technischen Universität München (TUM)
| |
Collapse
|
13
|
Kiechle M, Schem C, Lüftner D, Hamann X, Jünemann R, Tölg M, Köhler U. Prophylaxis with lipegfilgrastim in patients with primary breast cancer receiving dose dense chemotherapy: Results from the German NIS NADENS. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz265.061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Noske A, Ammann J, Wagner DC, Denkert C, Lebeau A, Sinn P, Kreipe HH, Baretton G, Steiger K, Kiechle M, Hieke-Schulz S, Roth W, Weichert W. Reproducibility and concordance of 4 clinically developed programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays in triple negative breast cancer (TNBC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz242.054] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
15
|
Ovaska K, Basrai M, Seethaler B, Kiechle M, Bischoff S. SUN-PO109: Effects of Western Style or Mediterranean Diet on Insulin Resistance Markers in Female BRCA1/2 Mutation Carriers (Libre Study). Clin Nutr 2019. [DOI: 10.1016/s0261-5614(19)32743-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
16
|
Johannigmann-Malek N, Paepke S, Kiechle M. Analyse implantatbasierter, netzunterstützter, plastisch-rekonstruktiver Mammaoperationen. Geburtshilfe Frauenheilkd 2019. [DOI: 10.1055/s-0039-1693859] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Affiliation(s)
| | - S Paepke
- Klinik und Poliklinik für Frauenheilkunde der Technischen Universität München
| | - M Kiechle
- Klinik und Poliklinik für Frauenheilkunde der Technischen Universität München
| |
Collapse
|
17
|
Ioannou I, Utpadel-Fischler D, Tölle T, Kiechle M, Ettl J. Feasibility of quantitative sensory testing (QST) in clinical routine as a tool to evaluate chemotherapy-induced peripheral neuropathy (CIPN) amongst breast cancer patients treated with taxanes. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz101.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
18
|
Ettl J, Blohmer JU, Denkert C, Keller M, Klein E, Kronenwett R, Neuser P, Paepke S, Schade-Brittinger C, Schnuppe K, Untch M, Wittenberg M, Kiechle M. Abstract OT1-12-03: RESCUE: Reaching for Evidence-baSed Chemotherapy Use in Endocrine sensitive breast cancer - A prospective health care study on risk assessment by the clinicomolecular test EndoPredict® and long-term patient outcome in early luminal breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot1-12-03] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In node negative and 1-3 positive nodes breast cancer patients with hormone receptor positive (HR+), HER2-negative (HER2-) early-stage breast cancer the indication for chemotherapy is based on clinical and pathologic risk stratification (tumor size, nodal status, grading, quantitative ER, progesterone receptor and Ki67). For further decision-making, the EndoPredict test, which combines a molecular signature with the clinical risk factors tumor size and nodal status, stratifies patients into “low risk" or “high risk” groups. Level I-B- evidence demonstrates, that EndoPredict predicts the 10 year cumulative risk of relapse and metastases in patients with HR+/HER2- primary breast cancer with endocrine treatment.
Aim: In the RESCUE-Trial we document distant metastasis-free survival (DMFS), disease free survival (DFS) and overall survival (OS) events in patients who had an EndoPredict test. The primary objective is to show that 10-year DMFS of patients tested as “low risk” by EndoPredict and treated with adjuvant endocrine therapy alone is >90 %. Secondary endpoints among others include DMFS, DFS, OS in patients with EPclin “low risk” versus “high risk”. Also the proportion of patients whose treatment was concordant and non-concordant with EndoPredict test results, will be analyzed for survival. The prognostic performance of classical prognostic factors (like tumor size, nodal status, grading, quantitative ER, progesterone receptor and Ki67 level) with respect to survival will also be assessed.
Eligibility: Patient with HR+/HER2- primary invasive breast cancer stage I/II and T1 to T3 with 0 to 3 positive lymph nodes will be eligible, if they had an EndoPredict test within three months before inclusion.
Methods: The EndoPredict test results, tumor board decision and anti-tumor therapy will be assessed. After one year, annually (for 10 years), patients will be evaluated for treatment compliance, recurrence, metastases, and survival. The primary endpoint will be analyzed by a Kaplan-Meyer estimate for which a one-sided lower 95 % confidence interval will be given. Several secondary endpoints will be assessed in three interim analyses after completion of the 1st, 3rd, 5th year and then finally after 10 years.
Accrual: Start of accrual is planned for July 2018. At least 26 sites in Germany and one site in Switzerland will be active.
Sponsor: The study is sponsored by the North-Eastern-German Society of Gynecological Oncology (NOGGO) e.V.
Contact Information: For further information, contact NOGGO via studies@noggo.de or the leading physician Dr. Johannes Ettl via johannes.ettl@tum.de.
Citation Format: Ettl J, Blohmer J-U, Denkert C, Keller M, Klein E, Kronenwett R, Neuser P, Paepke S, Schade-Brittinger C, Schnuppe K, Untch M, Wittenberg M, Kiechle M. RESCUE: Reaching for Evidence-baSed Chemotherapy Use in Endocrine sensitive breast cancer - A prospective health care study on risk assessment by the clinicomolecular test EndoPredict® and long-term patient outcome in early luminal breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT1-12-03.
Collapse
Affiliation(s)
- J Ettl
- Klinikum rechts der Isar of the Technical University of Munich, Munich, Germany; Charité Medical University Berlin, Berlin, Germany; North-Eastern German Society of Gynecological Oncology e.V., Berlin, Germany; Myriad International GmbH, Cologne, Germany; Center for Clinical Trials of the Philipps-University of Marburg, Marburg, Germany; Helios-Klinikum Berlin-Buch, Berlin, Germany; Klinikum rechts der Isar of the Technical University of Munich (Currently Off-Duty), Munich, Germany
| | - J-U Blohmer
- Klinikum rechts der Isar of the Technical University of Munich, Munich, Germany; Charité Medical University Berlin, Berlin, Germany; North-Eastern German Society of Gynecological Oncology e.V., Berlin, Germany; Myriad International GmbH, Cologne, Germany; Center for Clinical Trials of the Philipps-University of Marburg, Marburg, Germany; Helios-Klinikum Berlin-Buch, Berlin, Germany; Klinikum rechts der Isar of the Technical University of Munich (Currently Off-Duty), Munich, Germany
| | - C Denkert
- Klinikum rechts der Isar of the Technical University of Munich, Munich, Germany; Charité Medical University Berlin, Berlin, Germany; North-Eastern German Society of Gynecological Oncology e.V., Berlin, Germany; Myriad International GmbH, Cologne, Germany; Center for Clinical Trials of the Philipps-University of Marburg, Marburg, Germany; Helios-Klinikum Berlin-Buch, Berlin, Germany; Klinikum rechts der Isar of the Technical University of Munich (Currently Off-Duty), Munich, Germany
| | - M Keller
- Klinikum rechts der Isar of the Technical University of Munich, Munich, Germany; Charité Medical University Berlin, Berlin, Germany; North-Eastern German Society of Gynecological Oncology e.V., Berlin, Germany; Myriad International GmbH, Cologne, Germany; Center for Clinical Trials of the Philipps-University of Marburg, Marburg, Germany; Helios-Klinikum Berlin-Buch, Berlin, Germany; Klinikum rechts der Isar of the Technical University of Munich (Currently Off-Duty), Munich, Germany
| | - E Klein
- Klinikum rechts der Isar of the Technical University of Munich, Munich, Germany; Charité Medical University Berlin, Berlin, Germany; North-Eastern German Society of Gynecological Oncology e.V., Berlin, Germany; Myriad International GmbH, Cologne, Germany; Center for Clinical Trials of the Philipps-University of Marburg, Marburg, Germany; Helios-Klinikum Berlin-Buch, Berlin, Germany; Klinikum rechts der Isar of the Technical University of Munich (Currently Off-Duty), Munich, Germany
| | - R Kronenwett
- Klinikum rechts der Isar of the Technical University of Munich, Munich, Germany; Charité Medical University Berlin, Berlin, Germany; North-Eastern German Society of Gynecological Oncology e.V., Berlin, Germany; Myriad International GmbH, Cologne, Germany; Center for Clinical Trials of the Philipps-University of Marburg, Marburg, Germany; Helios-Klinikum Berlin-Buch, Berlin, Germany; Klinikum rechts der Isar of the Technical University of Munich (Currently Off-Duty), Munich, Germany
| | - P Neuser
- Klinikum rechts der Isar of the Technical University of Munich, Munich, Germany; Charité Medical University Berlin, Berlin, Germany; North-Eastern German Society of Gynecological Oncology e.V., Berlin, Germany; Myriad International GmbH, Cologne, Germany; Center for Clinical Trials of the Philipps-University of Marburg, Marburg, Germany; Helios-Klinikum Berlin-Buch, Berlin, Germany; Klinikum rechts der Isar of the Technical University of Munich (Currently Off-Duty), Munich, Germany
| | - S Paepke
- Klinikum rechts der Isar of the Technical University of Munich, Munich, Germany; Charité Medical University Berlin, Berlin, Germany; North-Eastern German Society of Gynecological Oncology e.V., Berlin, Germany; Myriad International GmbH, Cologne, Germany; Center for Clinical Trials of the Philipps-University of Marburg, Marburg, Germany; Helios-Klinikum Berlin-Buch, Berlin, Germany; Klinikum rechts der Isar of the Technical University of Munich (Currently Off-Duty), Munich, Germany
| | - C Schade-Brittinger
- Klinikum rechts der Isar of the Technical University of Munich, Munich, Germany; Charité Medical University Berlin, Berlin, Germany; North-Eastern German Society of Gynecological Oncology e.V., Berlin, Germany; Myriad International GmbH, Cologne, Germany; Center for Clinical Trials of the Philipps-University of Marburg, Marburg, Germany; Helios-Klinikum Berlin-Buch, Berlin, Germany; Klinikum rechts der Isar of the Technical University of Munich (Currently Off-Duty), Munich, Germany
| | - K Schnuppe
- Klinikum rechts der Isar of the Technical University of Munich, Munich, Germany; Charité Medical University Berlin, Berlin, Germany; North-Eastern German Society of Gynecological Oncology e.V., Berlin, Germany; Myriad International GmbH, Cologne, Germany; Center for Clinical Trials of the Philipps-University of Marburg, Marburg, Germany; Helios-Klinikum Berlin-Buch, Berlin, Germany; Klinikum rechts der Isar of the Technical University of Munich (Currently Off-Duty), Munich, Germany
| | - M Untch
- Klinikum rechts der Isar of the Technical University of Munich, Munich, Germany; Charité Medical University Berlin, Berlin, Germany; North-Eastern German Society of Gynecological Oncology e.V., Berlin, Germany; Myriad International GmbH, Cologne, Germany; Center for Clinical Trials of the Philipps-University of Marburg, Marburg, Germany; Helios-Klinikum Berlin-Buch, Berlin, Germany; Klinikum rechts der Isar of the Technical University of Munich (Currently Off-Duty), Munich, Germany
| | - M Wittenberg
- Klinikum rechts der Isar of the Technical University of Munich, Munich, Germany; Charité Medical University Berlin, Berlin, Germany; North-Eastern German Society of Gynecological Oncology e.V., Berlin, Germany; Myriad International GmbH, Cologne, Germany; Center for Clinical Trials of the Philipps-University of Marburg, Marburg, Germany; Helios-Klinikum Berlin-Buch, Berlin, Germany; Klinikum rechts der Isar of the Technical University of Munich (Currently Off-Duty), Munich, Germany
| | - M Kiechle
- Klinikum rechts der Isar of the Technical University of Munich, Munich, Germany; Charité Medical University Berlin, Berlin, Germany; North-Eastern German Society of Gynecological Oncology e.V., Berlin, Germany; Myriad International GmbH, Cologne, Germany; Center for Clinical Trials of the Philipps-University of Marburg, Marburg, Germany; Helios-Klinikum Berlin-Buch, Berlin, Germany; Klinikum rechts der Isar of the Technical University of Munich (Currently Off-Duty), Munich, Germany
| |
Collapse
|
19
|
Mayinger M, Reibelt A, Borm K, Ettl J, Kiechle M, Wilkens J, Combs S, Oechsner M, Duma M. Neuroanatomical Differences in the Brains of Cerebral Metastasized Breast Cancer Patients:Meningeal Carcinomatosa Patients vs. Brain Oligometastatic Patients vs. Multiple Metastastic Brain Patients. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
20
|
Ohlinger R, Alwafei Z, Thill M, Baumann K, Pursche T, Bangemann N, Mett R, Faridi A, Strittmatter HJ, Kiechle M, Paepke S. Präpektorale Implantateinlage in der plastisch-rekonstruktiven Mammachirurgie unter Verwendung des TiLOOP®BraPocket. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- R Ohlinger
- Universitätsmedizin Greifswald, Klinik und Poliklinik Frauenheilkunde und Geburtshilfe, Greifswald, Deutschland
| | - Z Alwafei
- Universitätsmedizin Greifswald, Klinik und Poliklinik Frauenheilkunde und Geburtshilfe, Greifswald, Deutschland
| | - M Thill
- Agaplesion Markus Krankenhaus, Frankfurt am Main, Deutschland
| | - K Baumann
- UKSH Campus Lübeck, Klinik für Frauenheilkunde und Geburtshilfe, Lübeck, Deutschland
| | - T Pursche
- UKSH Campus Lübeck, Klinik für Frauenheilkunde und Geburtshilfe, Lübeck, Deutschland
| | - N Bangemann
- Klinik für Gynäkologie mit Brustzentrum der Charité, Berlin, Deutschland
| | - R Mett
- HELIOS Klinikum Schwerin, Klinik für Plastische und Ästhetische Chirurgie, Schwerin, Deutschland
| | - A Faridi
- Vivantes Brustzentrum Am Urban, Berlin, Deutschland
| | | | - M Kiechle
- Klinikum rechts der Isar, TU München, Klinik und Poliklinik für Frauenheilkunde, München, Deutschland
| | - S Paepke
- Klinikum rechts der Isar, TU München, Klinik und Poliklinik für Frauenheilkunde, München, Deutschland
| |
Collapse
|
21
|
Dreyer T, Kuhn S, Jelsma J, Heithorst N, Schilling D, Sievert W, Multhoff G, Wege AK, Kiechle M, Bronger H. Das Chemokin CX3CL1 erhöht die Immuninfiltration, reduziert Tumorwachstum und -metastasierung und verbessert die Trastuzumab-Therapie in vitro und in vivo. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- T Dreyer
- Klinikum rechts der Isar, TU München, Klinik und Poliklinik für Frauenheilkunde, München, Deutschland
| | - S Kuhn
- Klinikum rechts der Isar, TU München, Institut für Klinische Chemie und Pathobiochemie, München, Deutschland
| | - J Jelsma
- Klinikum rechts der Isar, TU München, Klinik und Poliklinik für Frauenheilkunde, München, Deutschland
| | - N Heithorst
- Klinikum rechts der Isar, TU München, Klinik und Poliklinik für Frauenheilkunde, München, Deutschland
| | - D Schilling
- Klinikum rechts der Isar, TU München, Klinik für Strahlentherapie, München, Deutschland
| | - W Sievert
- Klinikum rechts der Isar, TU München, Klinik für Strahlentherapie, München, Deutschland
| | - G Multhoff
- Klinikum rechts der Isar, TU München, Klinik für Strahlentherapie, München, Deutschland
| | - AK Wege
- Universität Regensburg, Frauenklinik, München, Deutschland
| | - M Kiechle
- Klinikum rechts der Isar, TU München, Klinik und Poliklinik für Frauenheilkunde, München, Deutschland
| | - H Bronger
- Klinikum rechts der Isar, TU München, Klinik und Poliklinik für Frauenheilkunde, München, Deutschland
| |
Collapse
|
22
|
Rippinger N, Haun MW, Fischer C, Rhiem K, Hübbel A, Grill S, Kiechle M, Cremer FW, Kast K, Nguyen HP, Ditsch N, Kratz P, Pfister S, Pajtler KW, Speiser D, Seitz S, Glimm H, Maatouk I, Hahne A, Sutter C, Schmutzler RK, Dikow N, Sohn C, Schott S. Prophylactic surgery among germline TP53 mutation carriers in Germany – a multicentric observational study. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671357] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- N Rippinger
- University Hospital Heidelberg, Department of Gynaecology and Obstetrics, Heidelberg, Deutschland
| | - MW Haun
- University Hospital Heidelberg, Department of General Internal Medicine and Psychosomatics, Heidelberg, Deutschland
| | - C Fischer
- University Hospital Heidelberg, Institute of Human Genetics, Heidelberg, Deutschland
| | - K Rhiem
- University Hospital of Cologne, Department of Gynaecology and Obstetrics, Cologne, Deutschland
| | - A Hübbel
- University Hospital of Cologne, Department of Gynaecology and Obstetrics, Cologne, Deutschland
| | - S Grill
- Klinikum rechts der Isar; Technical University of Munich, Department of Gynaecology and Centre for Hereditary Breast and Ovarian Cancer, Munich, Deutschland
| | - M Kiechle
- Klinikum rechts der Isar; Technical University of Munich, Department of Gynaecology and Centre for Hereditary Breast and Ovarian Cancer, Munich, Deutschland
| | - FW Cremer
- SYNLAB Centre for Human Genetics, Mannheim, Deutschland
| | - K Kast
- Medical Faculty and University Hospital Carl Gustav Carus, Technical University Dresden, Department of Gynaecology and Obstetrics, Dresden, Deutschland
- National Center for Tumor Diseases, Partner Site Dresden, Dresden, Deutschland
- German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Dresden, Deutschland
| | - HP Nguyen
- University Hospital of Tuebingen, Institute of Medical Genetics and Applied Genomics, Tuebingen, Deutschland
- University of Bochum, Department of Human Genetics, Bochum, Deutschland
| | - N Ditsch
- Ludwig-Maximilians University, University Hospital of Munich, Department of Gynaecology and Obstetrics, Munich, Deutschland
| | - P Kratz
- Hannover Medical School, Paediatric Haematology and Oncology, Hannover, Deutschland
| | - S Pfister
- Hopp Children's Cancer Centre at the NCT Heidelberg (KiTZ), Heidelberg, Deutschland
- German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Division of Paediatric Neurooncology, Heidelberg, Deutschland
- University Hospital Heidelberg, Department of Paediatric Oncology, Hematology and Immunology, Heidelberg, Deutschland
| | - KW Pajtler
- Hopp Children's Cancer Centre at the NCT Heidelberg (KiTZ), Heidelberg, Deutschland
- German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Division of Paediatric Neurooncology, Heidelberg, Deutschland
- University Hospital Heidelberg, Department of Paediatric Oncology, Hematology and Immunology, Heidelberg, Deutschland
| | - D Speiser
- University Hospital Charité Berlin, Department of Gynaecology and Obstetrics, Berlin, Deutschland
| | - S Seitz
- University Medical Centre Regensburg, Department of Gynaecology and Obstetrics, Regensburg, Deutschland
| | - H Glimm
- National Center for Tumor Diseases (NCT), Heidelberg, Deutschland
| | - I Maatouk
- University Hospital Heidelberg, Department of General Internal Medicine and Psychosomatics, Heidelberg, Deutschland
| | - A Hahne
- BRCA Network, Hannover, Deutschland
| | - C Sutter
- University Hospital Heidelberg, Department of Human Genetics, Heidelberg, Deutschland
| | - RK Schmutzler
- University Hospital of Cologne, Department of Gynaecology and Obstetrics, Cologne, Deutschland
| | - N Dikow
- University Hospital Heidelberg, Department of Human Genetics, Heidelberg, Deutschland
| | - C Sohn
- University Hospital Heidelberg, Department of Gynaecology and Obstetrics, Heidelberg, Deutschland
| | - S Schott
- University Hospital Heidelberg, Department of Gynaecology and Obstetrics, Heidelberg, Deutschland
| |
Collapse
|
23
|
Stassek J, Müller D, Kiechle M, Dorn J. Operative Sanierung eines gigantischen Stromapolyp der Vulva mit verkomplizierender Acne inversa – ein Fallbericht. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- J Stassek
- Klinikum rechts der Isar, TU München, Frauenklinik, München, Deutschland
| | - D Müller
- Klinikum rechts der Isar, TU München, Frauenklinik, München, Deutschland
| | - M Kiechle
- Klinikum rechts der Isar, TU München, Frauenklinik, München, Deutschland
| | - J Dorn
- Klinikum rechts der Isar, TU München, Frauenklinik, München, Deutschland
| |
Collapse
|
24
|
Bronger H, Dreyer T, Demlehner J, Kuhn S, Kraeft S, Multhoff G, Kiechle M. CXCL9 wird durch den COX-Inhibitor Indomethacin aus Mammakarzinomzellen freigesetzt und hemmt das Tumorwachstum in vivo. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- H Bronger
- Klinikum rechts der Isar, TU München, Klinik und Poliklinik für Frauenheilkunde, München, Deutschland
| | - T Dreyer
- Klinikum rechts der Isar, TU München, Klinik und Poliklinik für Frauenheilkunde, München, Deutschland
| | - J Demlehner
- Klinikum rechts der Isar, TU München, Klinik und Poliklinik für Frauenheilkunde, München, Deutschland
| | - S Kuhn
- Klinikum rechts der Isar, TU München, Institut für Klinische Chemie und Pathobiochemie, München, Deutschland
| | - S Kraeft
- Klinikum rechts der Isar, TU München, Klinik und Poliklinik für Frauenheilkunde, München, Deutschland
| | - G Multhoff
- Klinikum rechts der Isar, TU München, Klinik für Strahlentherapie, München, Deutschland
| | - M Kiechle
- Klinikum rechts der Isar, TU München, Klinik und Poliklinik für Frauenheilkunde, München, Deutschland
| |
Collapse
|
25
|
Jesinghaus M, Strehl J, Boxberg M, Wenzel A, Brühl F, Konukiewitz B, Schlitter AM, Steiger K, Warth A, Schnelzer A, Kiechle M, Beckmann MW, Noske A, Hartmann A, Mehlhorn G, Weichert W, Koch M. Introducing a novel highly prognostic grading scheme based on tumor budding and cell nest size for squamous cell carcinoma of the uterine cervix. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- M Jesinghaus
- Pathologisches Institut der Technischen Universität München, München, Deutschland
- German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Deutschland
| | - J Strehl
- Pathologisches Institut Universitätsklinikum Erlangen, Erlangen, Deutschland
| | - M Boxberg
- Pathologisches Institut der Technischen Universität München, München, Deutschland
| | - A Wenzel
- Pathologisches Institut der Technischen Universität München, München, Deutschland
| | - F Brühl
- Pathologisches Institut der Technischen Universität München, München, Deutschland
| | - B Konukiewitz
- Pathologisches Institut der Technischen Universität München, München, Deutschland
| | - AM Schlitter
- Pathologisches Institut der Technischen Universität München, München, Deutschland
| | - K Steiger
- Pathologisches Institut der Technischen Universität München, München, Deutschland
| | - A Warth
- Pathologisches Institut der Universität Heidelberg, Heidelberg, Deutschland
| | - A Schnelzer
- Frauenklinik der Technischen Universität München, München, Deutschland
| | - M Kiechle
- Frauenklinik der Technischen Universität München, München, Deutschland
| | - MW Beckmann
- Frauenklinik Universitätsklinikum Erlangen, Gynäkologische Onkologie, Erlangen, Deutschland
| | - A Noske
- Pathologisches Institut der Technischen Universität München, München, Deutschland
| | - A Hartmann
- Pathologisches Institut Universitätsklinikum Erlangen, Erlangen, Deutschland
| | - G Mehlhorn
- Pathologisches Institut Universitätsklinikum Erlangen, Erlangen, Deutschland
- Frauenklinik Universitätsklinikum Erlangen, Gynäkologische Onkologie, Erlangen, Deutschland
| | - W Weichert
- Pathologisches Institut der Technischen Universität München, München, Deutschland
- German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Deutschland
| | - M Koch
- Frauenklinik Universitätsklinikum Erlangen, Gynäkologische Onkologie, Erlangen, Deutschland
| |
Collapse
|
26
|
González EU, Ovaska K, Seethaler B, Basrai M, Yahiaoui-Doktor M, Lehnert K, Vetter W, Engel C, Halle M, Siniatchkin M, Kiechle M, Bischoff S. Effects of a lifestyle intervention study for mediterranean diet on the fatty acid composition in plasma and erythrocyte membrane. Clin Nutr 2018. [DOI: 10.1016/j.clnu.2018.06.1319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
27
|
Schürger N, Klein E, Hapfelmeier A, Kiechle M, Paepke D. Wunsch nach integrativer Medizin in Schwangerschaft und Wochenbett: Ergebnisse einer Umfrage. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1655526] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- N Schürger
- Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München
| | - E Klein
- Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München
| | - A Hapfelmeier
- Institut für Medizinische Statistik und Epidemiologie, Technische Universität München
| | - M Kiechle
- Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München
| | - D Paepke
- Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München
| |
Collapse
|
28
|
Wiedeck C, Klein E, Hapfelmeier A, Kiechle M, Paepke D. Prävalenz und Prädiktoren für die Nicht-Anwendung komplementärmedizinischer Therapien bei Patientinnen mit Mamma- oder gynäkologischen Krebserkrankungen. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1655518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- C Wiedeck
- Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München
| | - E Klein
- Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München
| | - A Hapfelmeier
- Institut für Medizinische Statistik und Epidemiologie, Technische Universität München
| | - M Kiechle
- Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München
| | - D Paepke
- Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München
| |
Collapse
|
29
|
Mathes S, Klein E, Große Lackmann K, Pintac-Pisar A, Dalic M, Ackermann U, Strobl K, Halle M, Kiechle M, Paepke D. Evaluation eines Integrativen Begleitprogramms für Patientinnen mit Mamma- und gynäkologischen Karzinomen unter Systemtherapie an der Frauenklinik rechts der Isar der TU München. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1655532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- S Mathes
- Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München
| | - E Klein
- Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München
| | - K Große Lackmann
- Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München
| | - A Pintac-Pisar
- Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München
| | - M Dalic
- Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München
| | - U Ackermann
- Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München
| | - K Strobl
- Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München
| | - M Halle
- Zentrum für Prävention und Sportmedizin der TU München, Klinikum rechts der Isar, Technische Universität München
| | - M Kiechle
- Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München
| | - D Paepke
- Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München
| |
Collapse
|
30
|
Drozdoff L, Klein E, Kiechle M, Paepke D. Komplementärmedizin unter Systemtherapie in der gynäkologischen Onkologie. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1655539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- L Drozdoff
- Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München
| | - E Klein
- Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München
| | - M Kiechle
- Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München
| | - D Paepke
- Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München
| |
Collapse
|
31
|
Paepke S, Wilhelm OG, Schmitt M, Noske A, Schricker G, Napieralski R, Vetter M, Thomssen C, Perkins J, Lauber J, Ulm K, Martens JWM, Weichert W, Kiechle M. PITX2 DNA-Methylierung: Erster klinisch validierter prädiktiver Marker zur Vorhersage des Ansprechens auf anthrazyklin-basierte Chemotherapie bei Brustkrebspatientinnen mit hohem Rezidivrisiko. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1655534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- S Paepke
- Klinik und Poliklinik für Frauenheilkunde/Institut für Pathologie, Klinikum rechts der Isar, Technische Universität München, Comprehensive Cancer Center; Qiagen GmbH, Hilden und Therawis Diagnostics GmbH München, Deutschland
| | - OG Wilhelm
- Klinik und Poliklinik für Frauenheilkunde/Institut für Pathologie, Klinikum rechts der Isar, Technische Universität München, Comprehensive Cancer Center; Qiagen GmbH, Hilden und Therawis Diagnostics GmbH München, Deutschland
| | - M Schmitt
- Klinik und Poliklinik für Frauenheilkunde/Institut für Pathologie, Klinikum rechts der Isar, Technische Universität München, Comprehensive Cancer Center; Qiagen GmbH, Hilden und Therawis Diagnostics GmbH München, Deutschland
| | - A Noske
- Klinik und Poliklinik für Frauenheilkunde/Institut für Pathologie, Klinikum rechts der Isar, Technische Universität München, Comprehensive Cancer Center; Qiagen GmbH, Hilden und Therawis Diagnostics GmbH München, Deutschland
| | - G Schricker
- Klinik und Poliklinik für Frauenheilkunde/Institut für Pathologie, Klinikum rechts der Isar, Technische Universität München, Comprehensive Cancer Center; Qiagen GmbH, Hilden und Therawis Diagnostics GmbH München, Deutschland
| | - R Napieralski
- Klinik und Poliklinik für Frauenheilkunde/Institut für Pathologie, Klinikum rechts der Isar, Technische Universität München, Comprehensive Cancer Center; Qiagen GmbH, Hilden und Therawis Diagnostics GmbH München, Deutschland
| | - M Vetter
- Klinik und Poliklinik für Frauenheilkunde/Institut für Pathologie, Klinikum rechts der Isar, Technische Universität München, Comprehensive Cancer Center; Qiagen GmbH, Hilden und Therawis Diagnostics GmbH München, Deutschland
| | - C Thomssen
- Klinik und Poliklinik für Frauenheilkunde/Institut für Pathologie, Klinikum rechts der Isar, Technische Universität München, Comprehensive Cancer Center; Qiagen GmbH, Hilden und Therawis Diagnostics GmbH München, Deutschland
| | - J Perkins
- Klinik und Poliklinik für Frauenheilkunde/Institut für Pathologie, Klinikum rechts der Isar, Technische Universität München, Comprehensive Cancer Center; Qiagen GmbH, Hilden und Therawis Diagnostics GmbH München, Deutschland
| | - J Lauber
- Klinik und Poliklinik für Frauenheilkunde/Institut für Pathologie, Klinikum rechts der Isar, Technische Universität München, Comprehensive Cancer Center; Qiagen GmbH, Hilden und Therawis Diagnostics GmbH München, Deutschland
| | - K Ulm
- Klinik und Poliklinik für Frauenheilkunde/Institut für Pathologie, Klinikum rechts der Isar, Technische Universität München, Comprehensive Cancer Center; Qiagen GmbH, Hilden und Therawis Diagnostics GmbH München, Deutschland
| | - JWM Martens
- Klinik und Poliklinik für Frauenheilkunde/Institut für Pathologie, Klinikum rechts der Isar, Technische Universität München, Comprehensive Cancer Center; Qiagen GmbH, Hilden und Therawis Diagnostics GmbH München, Deutschland
| | - W Weichert
- Klinik und Poliklinik für Frauenheilkunde/Institut für Pathologie, Klinikum rechts der Isar, Technische Universität München, Comprehensive Cancer Center; Qiagen GmbH, Hilden und Therawis Diagnostics GmbH München, Deutschland
| | - M Kiechle
- Klinik und Poliklinik für Frauenheilkunde/Institut für Pathologie, Klinikum rechts der Isar, Technische Universität München, Comprehensive Cancer Center; Qiagen GmbH, Hilden und Therawis Diagnostics GmbH München, Deutschland
| |
Collapse
|
32
|
Welz B, Hapfelmeier A, Kiechle M, Paepke D. Retrospektive Datenauswertung zur Inanspruchnahme, Compliance, Verträglichkeit und Lebensqualität in Abhängigkeit einer komplementärmedizinischen Behandlung bei Patientinnen mit malignen gynäkologischen Tumoren. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1655512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- B Welz
- Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München
| | - A Hapfelmeier
- Institut für Medizinische Statistik und Epidemiologie, Technische Universität München
| | - M Kiechle
- Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München
| | - D Paepke
- Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München
| |
Collapse
|
33
|
Kessel K, Kessel C, Vogel M, Bier H, Biedermann T, Friess H, Herschbach P, Von Eisenhart-Rothe R, Meyer B, Kiechle M, Keller U, Peschel C, Schmid R, Schwaiger M, Combs S. OC-0094: Cancer Clinical Trials - survey evaluating patient participation and attitude in an Oncology Center. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)30404-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
34
|
Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Weiss E, Böhmer S, Kreienberg R, Du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Kuhn W. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. Ann Oncol 2017; 28:2899. [PMID: 27634692 DOI: 10.1093/annonc/mdw349] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/08/2023] Open
Affiliation(s)
- U Nitz
- Women's Clinic, Heinrich-Heine-University Duesseldorf, Duesseldorf; West German Study Group, Moenchengladbach; Breast Center Niederrhein, Ev. Bethesda Hospital, Moenchengladbach; Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen; Institute of Pathology, Hannover Medical School, Hannover; Institute of Pathology, University Clinics Erlangen, Erlangen; Trium Analysis Online GmbH, Munich; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg; Department of Obstetrics and Gynecology, Staedtisches Klinikum, Frankfurt; Clinics Deggendorf Mammacenter Ostbayern, Deggendorf; Breast Center, St Josephs-Hospital, Wiesbaden; Women's Clinic, Kreiskrankenhaus Boeblingen, Boeblingen; Department of Obstetrics and Gynecology, Ev. Hospital Oberhausen, Oberhausen; Breast Center, University Women's Clinic Ulm, Ulm; Department of Gynecology and Oncology, Dr. Horst-Schmidt-Klinik GmbH, Wiesbaden; Department of Gynecology and Obstetrics, Klinikum Rechts der Isar der Technischen Universität Muenchen (TUM), Munich; Breast Center, Women's Clinic and CCCLMU of the University of Munich, Munich; Department of Gynecology, University Hospital Bonn, Bonn, Germany.
| | - O Gluz
- Women's Clinic, Heinrich-Heine-University Duesseldorf, Duesseldorf; West German Study Group, Moenchengladbach; Breast Center Niederrhein, Ev. Bethesda Hospital, Moenchengladbach; Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen; Institute of Pathology, Hannover Medical School, Hannover; Institute of Pathology, University Clinics Erlangen, Erlangen; Trium Analysis Online GmbH, Munich; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg; Department of Obstetrics and Gynecology, Staedtisches Klinikum, Frankfurt; Clinics Deggendorf Mammacenter Ostbayern, Deggendorf; Breast Center, St Josephs-Hospital, Wiesbaden; Women's Clinic, Kreiskrankenhaus Boeblingen, Boeblingen; Department of Obstetrics and Gynecology, Ev. Hospital Oberhausen, Oberhausen; Breast Center, University Women's Clinic Ulm, Ulm; Department of Gynecology and Oncology, Dr. Horst-Schmidt-Klinik GmbH, Wiesbaden; Department of Gynecology and Obstetrics, Klinikum Rechts der Isar der Technischen Universität Muenchen (TUM), Munich; Breast Center, Women's Clinic and CCCLMU of the University of Munich, Munich; Department of Gynecology, University Hospital Bonn, Bonn, Germany
| | - J Huober
- Women's Clinic, Heinrich-Heine-University Duesseldorf, Duesseldorf; West German Study Group, Moenchengladbach; Breast Center Niederrhein, Ev. Bethesda Hospital, Moenchengladbach; Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen; Institute of Pathology, Hannover Medical School, Hannover; Institute of Pathology, University Clinics Erlangen, Erlangen; Trium Analysis Online GmbH, Munich; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg; Department of Obstetrics and Gynecology, Staedtisches Klinikum, Frankfurt; Clinics Deggendorf Mammacenter Ostbayern, Deggendorf; Breast Center, St Josephs-Hospital, Wiesbaden; Women's Clinic, Kreiskrankenhaus Boeblingen, Boeblingen; Department of Obstetrics and Gynecology, Ev. Hospital Oberhausen, Oberhausen; Breast Center, University Women's Clinic Ulm, Ulm; Department of Gynecology and Oncology, Dr. Horst-Schmidt-Klinik GmbH, Wiesbaden; Department of Gynecology and Obstetrics, Klinikum Rechts der Isar der Technischen Universität Muenchen (TUM), Munich; Breast Center, Women's Clinic and CCCLMU of the University of Munich, Munich; Department of Gynecology, University Hospital Bonn, Bonn, Germany
| | - H H Kreipe
- Women's Clinic, Heinrich-Heine-University Duesseldorf, Duesseldorf; West German Study Group, Moenchengladbach; Breast Center Niederrhein, Ev. Bethesda Hospital, Moenchengladbach; Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen; Institute of Pathology, Hannover Medical School, Hannover; Institute of Pathology, University Clinics Erlangen, Erlangen; Trium Analysis Online GmbH, Munich; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg; Department of Obstetrics and Gynecology, Staedtisches Klinikum, Frankfurt; Clinics Deggendorf Mammacenter Ostbayern, Deggendorf; Breast Center, St Josephs-Hospital, Wiesbaden; Women's Clinic, Kreiskrankenhaus Boeblingen, Boeblingen; Department of Obstetrics and Gynecology, Ev. Hospital Oberhausen, Oberhausen; Breast Center, University Women's Clinic Ulm, Ulm; Department of Gynecology and Oncology, Dr. Horst-Schmidt-Klinik GmbH, Wiesbaden; Department of Gynecology and Obstetrics, Klinikum Rechts der Isar der Technischen Universität Muenchen (TUM), Munich; Breast Center, Women's Clinic and CCCLMU of the University of Munich, Munich; Department of Gynecology, University Hospital Bonn, Bonn, Germany
| | - R E Kates
- Women's Clinic, Heinrich-Heine-University Duesseldorf, Duesseldorf; West German Study Group, Moenchengladbach; Breast Center Niederrhein, Ev. Bethesda Hospital, Moenchengladbach; Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen; Institute of Pathology, Hannover Medical School, Hannover; Institute of Pathology, University Clinics Erlangen, Erlangen; Trium Analysis Online GmbH, Munich; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg; Department of Obstetrics and Gynecology, Staedtisches Klinikum, Frankfurt; Clinics Deggendorf Mammacenter Ostbayern, Deggendorf; Breast Center, St Josephs-Hospital, Wiesbaden; Women's Clinic, Kreiskrankenhaus Boeblingen, Boeblingen; Department of Obstetrics and Gynecology, Ev. Hospital Oberhausen, Oberhausen; Breast Center, University Women's Clinic Ulm, Ulm; Department of Gynecology and Oncology, Dr. Horst-Schmidt-Klinik GmbH, Wiesbaden; Department of Gynecology and Obstetrics, Klinikum Rechts der Isar der Technischen Universität Muenchen (TUM), Munich; Breast Center, Women's Clinic and CCCLMU of the University of Munich, Munich; Department of Gynecology, University Hospital Bonn, Bonn, Germany
| | - A Hartmann
- Women's Clinic, Heinrich-Heine-University Duesseldorf, Duesseldorf; West German Study Group, Moenchengladbach; Breast Center Niederrhein, Ev. Bethesda Hospital, Moenchengladbach; Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen; Institute of Pathology, Hannover Medical School, Hannover; Institute of Pathology, University Clinics Erlangen, Erlangen; Trium Analysis Online GmbH, Munich; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg; Department of Obstetrics and Gynecology, Staedtisches Klinikum, Frankfurt; Clinics Deggendorf Mammacenter Ostbayern, Deggendorf; Breast Center, St Josephs-Hospital, Wiesbaden; Women's Clinic, Kreiskrankenhaus Boeblingen, Boeblingen; Department of Obstetrics and Gynecology, Ev. Hospital Oberhausen, Oberhausen; Breast Center, University Women's Clinic Ulm, Ulm; Department of Gynecology and Oncology, Dr. Horst-Schmidt-Klinik GmbH, Wiesbaden; Department of Gynecology and Obstetrics, Klinikum Rechts der Isar der Technischen Universität Muenchen (TUM), Munich; Breast Center, Women's Clinic and CCCLMU of the University of Munich, Munich; Department of Gynecology, University Hospital Bonn, Bonn, Germany
| | - R Erber
- Women's Clinic, Heinrich-Heine-University Duesseldorf, Duesseldorf; West German Study Group, Moenchengladbach; Breast Center Niederrhein, Ev. Bethesda Hospital, Moenchengladbach; Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen; Institute of Pathology, Hannover Medical School, Hannover; Institute of Pathology, University Clinics Erlangen, Erlangen; Trium Analysis Online GmbH, Munich; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg; Department of Obstetrics and Gynecology, Staedtisches Klinikum, Frankfurt; Clinics Deggendorf Mammacenter Ostbayern, Deggendorf; Breast Center, St Josephs-Hospital, Wiesbaden; Women's Clinic, Kreiskrankenhaus Boeblingen, Boeblingen; Department of Obstetrics and Gynecology, Ev. Hospital Oberhausen, Oberhausen; Breast Center, University Women's Clinic Ulm, Ulm; Department of Gynecology and Oncology, Dr. Horst-Schmidt-Klinik GmbH, Wiesbaden; Department of Gynecology and Obstetrics, Klinikum Rechts der Isar der Technischen Universität Muenchen (TUM), Munich; Breast Center, Women's Clinic and CCCLMU of the University of Munich, Munich; Department of Gynecology, University Hospital Bonn, Bonn, Germany
| | - Z Moustafa
- Women's Clinic, Heinrich-Heine-University Duesseldorf, Duesseldorf; West German Study Group, Moenchengladbach; Breast Center Niederrhein, Ev. Bethesda Hospital, Moenchengladbach; Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen; Institute of Pathology, Hannover Medical School, Hannover; Institute of Pathology, University Clinics Erlangen, Erlangen; Trium Analysis Online GmbH, Munich; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg; Department of Obstetrics and Gynecology, Staedtisches Klinikum, Frankfurt; Clinics Deggendorf Mammacenter Ostbayern, Deggendorf; Breast Center, St Josephs-Hospital, Wiesbaden; Women's Clinic, Kreiskrankenhaus Boeblingen, Boeblingen; Department of Obstetrics and Gynecology, Ev. Hospital Oberhausen, Oberhausen; Breast Center, University Women's Clinic Ulm, Ulm; Department of Gynecology and Oncology, Dr. Horst-Schmidt-Klinik GmbH, Wiesbaden; Department of Gynecology and Obstetrics, Klinikum Rechts der Isar der Technischen Universität Muenchen (TUM), Munich; Breast Center, Women's Clinic and CCCLMU of the University of Munich, Munich; Department of Gynecology, University Hospital Bonn, Bonn, Germany
| | - M Scholz
- Women's Clinic, Heinrich-Heine-University Duesseldorf, Duesseldorf; West German Study Group, Moenchengladbach; Breast Center Niederrhein, Ev. Bethesda Hospital, Moenchengladbach; Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen; Institute of Pathology, Hannover Medical School, Hannover; Institute of Pathology, University Clinics Erlangen, Erlangen; Trium Analysis Online GmbH, Munich; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg; Department of Obstetrics and Gynecology, Staedtisches Klinikum, Frankfurt; Clinics Deggendorf Mammacenter Ostbayern, Deggendorf; Breast Center, St Josephs-Hospital, Wiesbaden; Women's Clinic, Kreiskrankenhaus Boeblingen, Boeblingen; Department of Obstetrics and Gynecology, Ev. Hospital Oberhausen, Oberhausen; Breast Center, University Women's Clinic Ulm, Ulm; Department of Gynecology and Oncology, Dr. Horst-Schmidt-Klinik GmbH, Wiesbaden; Department of Gynecology and Obstetrics, Klinikum Rechts der Isar der Technischen Universität Muenchen (TUM), Munich; Breast Center, Women's Clinic and CCCLMU of the University of Munich, Munich; Department of Gynecology, University Hospital Bonn, Bonn, Germany
| | - B Lisboa
- Women's Clinic, Heinrich-Heine-University Duesseldorf, Duesseldorf; West German Study Group, Moenchengladbach; Breast Center Niederrhein, Ev. Bethesda Hospital, Moenchengladbach; Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen; Institute of Pathology, Hannover Medical School, Hannover; Institute of Pathology, University Clinics Erlangen, Erlangen; Trium Analysis Online GmbH, Munich; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg; Department of Obstetrics and Gynecology, Staedtisches Klinikum, Frankfurt; Clinics Deggendorf Mammacenter Ostbayern, Deggendorf; Breast Center, St Josephs-Hospital, Wiesbaden; Women's Clinic, Kreiskrankenhaus Boeblingen, Boeblingen; Department of Obstetrics and Gynecology, Ev. Hospital Oberhausen, Oberhausen; Breast Center, University Women's Clinic Ulm, Ulm; Department of Gynecology and Oncology, Dr. Horst-Schmidt-Klinik GmbH, Wiesbaden; Department of Gynecology and Obstetrics, Klinikum Rechts der Isar der Technischen Universität Muenchen (TUM), Munich; Breast Center, Women's Clinic and CCCLMU of the University of Munich, Munich; Department of Gynecology, University Hospital Bonn, Bonn, Germany
| | - S Mohrmann
- Women's Clinic, Heinrich-Heine-University Duesseldorf, Duesseldorf; West German Study Group, Moenchengladbach; Breast Center Niederrhein, Ev. Bethesda Hospital, Moenchengladbach; Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen; Institute of Pathology, Hannover Medical School, Hannover; Institute of Pathology, University Clinics Erlangen, Erlangen; Trium Analysis Online GmbH, Munich; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg; Department of Obstetrics and Gynecology, Staedtisches Klinikum, Frankfurt; Clinics Deggendorf Mammacenter Ostbayern, Deggendorf; Breast Center, St Josephs-Hospital, Wiesbaden; Women's Clinic, Kreiskrankenhaus Boeblingen, Boeblingen; Department of Obstetrics and Gynecology, Ev. Hospital Oberhausen, Oberhausen; Breast Center, University Women's Clinic Ulm, Ulm; Department of Gynecology and Oncology, Dr. Horst-Schmidt-Klinik GmbH, Wiesbaden; Department of Gynecology and Obstetrics, Klinikum Rechts der Isar der Technischen Universität Muenchen (TUM), Munich; Breast Center, Women's Clinic and CCCLMU of the University of Munich, Munich; Department of Gynecology, University Hospital Bonn, Bonn, Germany
| | - V Möbus
- Women's Clinic, Heinrich-Heine-University Duesseldorf, Duesseldorf; West German Study Group, Moenchengladbach; Breast Center Niederrhein, Ev. Bethesda Hospital, Moenchengladbach; Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen; Institute of Pathology, Hannover Medical School, Hannover; Institute of Pathology, University Clinics Erlangen, Erlangen; Trium Analysis Online GmbH, Munich; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg; Department of Obstetrics and Gynecology, Staedtisches Klinikum, Frankfurt; Clinics Deggendorf Mammacenter Ostbayern, Deggendorf; Breast Center, St Josephs-Hospital, Wiesbaden; Women's Clinic, Kreiskrankenhaus Boeblingen, Boeblingen; Department of Obstetrics and Gynecology, Ev. Hospital Oberhausen, Oberhausen; Breast Center, University Women's Clinic Ulm, Ulm; Department of Gynecology and Oncology, Dr. Horst-Schmidt-Klinik GmbH, Wiesbaden; Department of Gynecology and Obstetrics, Klinikum Rechts der Isar der Technischen Universität Muenchen (TUM), Munich; Breast Center, Women's Clinic and CCCLMU of the University of Munich, Munich; Department of Gynecology, University Hospital Bonn, Bonn, Germany
| | - D Augustin
- Women's Clinic, Heinrich-Heine-University Duesseldorf, Duesseldorf; West German Study Group, Moenchengladbach; Breast Center Niederrhein, Ev. Bethesda Hospital, Moenchengladbach; Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen; Institute of Pathology, Hannover Medical School, Hannover; Institute of Pathology, University Clinics Erlangen, Erlangen; Trium Analysis Online GmbH, Munich; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg; Department of Obstetrics and Gynecology, Staedtisches Klinikum, Frankfurt; Clinics Deggendorf Mammacenter Ostbayern, Deggendorf; Breast Center, St Josephs-Hospital, Wiesbaden; Women's Clinic, Kreiskrankenhaus Boeblingen, Boeblingen; Department of Obstetrics and Gynecology, Ev. Hospital Oberhausen, Oberhausen; Breast Center, University Women's Clinic Ulm, Ulm; Department of Gynecology and Oncology, Dr. Horst-Schmidt-Klinik GmbH, Wiesbaden; Department of Gynecology and Obstetrics, Klinikum Rechts der Isar der Technischen Universität Muenchen (TUM), Munich; Breast Center, Women's Clinic and CCCLMU of the University of Munich, Munich; Department of Gynecology, University Hospital Bonn, Bonn, Germany
| | - G Hoffmann
- Women's Clinic, Heinrich-Heine-University Duesseldorf, Duesseldorf; West German Study Group, Moenchengladbach; Breast Center Niederrhein, Ev. Bethesda Hospital, Moenchengladbach; Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen; Institute of Pathology, Hannover Medical School, Hannover; Institute of Pathology, University Clinics Erlangen, Erlangen; Trium Analysis Online GmbH, Munich; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg; Department of Obstetrics and Gynecology, Staedtisches Klinikum, Frankfurt; Clinics Deggendorf Mammacenter Ostbayern, Deggendorf; Breast Center, St Josephs-Hospital, Wiesbaden; Women's Clinic, Kreiskrankenhaus Boeblingen, Boeblingen; Department of Obstetrics and Gynecology, Ev. Hospital Oberhausen, Oberhausen; Breast Center, University Women's Clinic Ulm, Ulm; Department of Gynecology and Oncology, Dr. Horst-Schmidt-Klinik GmbH, Wiesbaden; Department of Gynecology and Obstetrics, Klinikum Rechts der Isar der Technischen Universität Muenchen (TUM), Munich; Breast Center, Women's Clinic and CCCLMU of the University of Munich, Munich; Department of Gynecology, University Hospital Bonn, Bonn, Germany
| | - E Weiss
- Women's Clinic, Heinrich-Heine-University Duesseldorf, Duesseldorf; West German Study Group, Moenchengladbach; Breast Center Niederrhein, Ev. Bethesda Hospital, Moenchengladbach; Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen; Institute of Pathology, Hannover Medical School, Hannover; Institute of Pathology, University Clinics Erlangen, Erlangen; Trium Analysis Online GmbH, Munich; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg; Department of Obstetrics and Gynecology, Staedtisches Klinikum, Frankfurt; Clinics Deggendorf Mammacenter Ostbayern, Deggendorf; Breast Center, St Josephs-Hospital, Wiesbaden; Women's Clinic, Kreiskrankenhaus Boeblingen, Boeblingen; Department of Obstetrics and Gynecology, Ev. Hospital Oberhausen, Oberhausen; Breast Center, University Women's Clinic Ulm, Ulm; Department of Gynecology and Oncology, Dr. Horst-Schmidt-Klinik GmbH, Wiesbaden; Department of Gynecology and Obstetrics, Klinikum Rechts der Isar der Technischen Universität Muenchen (TUM), Munich; Breast Center, Women's Clinic and CCCLMU of the University of Munich, Munich; Department of Gynecology, University Hospital Bonn, Bonn, Germany
| | - S Böhmer
- Women's Clinic, Heinrich-Heine-University Duesseldorf, Duesseldorf; West German Study Group, Moenchengladbach; Breast Center Niederrhein, Ev. Bethesda Hospital, Moenchengladbach; Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen; Institute of Pathology, Hannover Medical School, Hannover; Institute of Pathology, University Clinics Erlangen, Erlangen; Trium Analysis Online GmbH, Munich; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg; Department of Obstetrics and Gynecology, Staedtisches Klinikum, Frankfurt; Clinics Deggendorf Mammacenter Ostbayern, Deggendorf; Breast Center, St Josephs-Hospital, Wiesbaden; Women's Clinic, Kreiskrankenhaus Boeblingen, Boeblingen; Department of Obstetrics and Gynecology, Ev. Hospital Oberhausen, Oberhausen; Breast Center, University Women's Clinic Ulm, Ulm; Department of Gynecology and Oncology, Dr. Horst-Schmidt-Klinik GmbH, Wiesbaden; Department of Gynecology and Obstetrics, Klinikum Rechts der Isar der Technischen Universität Muenchen (TUM), Munich; Breast Center, Women's Clinic and CCCLMU of the University of Munich, Munich; Department of Gynecology, University Hospital Bonn, Bonn, Germany
| | - R Kreienberg
- Women's Clinic, Heinrich-Heine-University Duesseldorf, Duesseldorf; West German Study Group, Moenchengladbach; Breast Center Niederrhein, Ev. Bethesda Hospital, Moenchengladbach; Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen; Institute of Pathology, Hannover Medical School, Hannover; Institute of Pathology, University Clinics Erlangen, Erlangen; Trium Analysis Online GmbH, Munich; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg; Department of Obstetrics and Gynecology, Staedtisches Klinikum, Frankfurt; Clinics Deggendorf Mammacenter Ostbayern, Deggendorf; Breast Center, St Josephs-Hospital, Wiesbaden; Women's Clinic, Kreiskrankenhaus Boeblingen, Boeblingen; Department of Obstetrics and Gynecology, Ev. Hospital Oberhausen, Oberhausen; Breast Center, University Women's Clinic Ulm, Ulm; Department of Gynecology and Oncology, Dr. Horst-Schmidt-Klinik GmbH, Wiesbaden; Department of Gynecology and Obstetrics, Klinikum Rechts der Isar der Technischen Universität Muenchen (TUM), Munich; Breast Center, Women's Clinic and CCCLMU of the University of Munich, Munich; Department of Gynecology, University Hospital Bonn, Bonn, Germany
| | - A Du Bois
- Women's Clinic, Heinrich-Heine-University Duesseldorf, Duesseldorf; West German Study Group, Moenchengladbach; Breast Center Niederrhein, Ev. Bethesda Hospital, Moenchengladbach; Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen; Institute of Pathology, Hannover Medical School, Hannover; Institute of Pathology, University Clinics Erlangen, Erlangen; Trium Analysis Online GmbH, Munich; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg; Department of Obstetrics and Gynecology, Staedtisches Klinikum, Frankfurt; Clinics Deggendorf Mammacenter Ostbayern, Deggendorf; Breast Center, St Josephs-Hospital, Wiesbaden; Women's Clinic, Kreiskrankenhaus Boeblingen, Boeblingen; Department of Obstetrics and Gynecology, Ev. Hospital Oberhausen, Oberhausen; Breast Center, University Women's Clinic Ulm, Ulm; Department of Gynecology and Oncology, Dr. Horst-Schmidt-Klinik GmbH, Wiesbaden; Department of Gynecology and Obstetrics, Klinikum Rechts der Isar der Technischen Universität Muenchen (TUM), Munich; Breast Center, Women's Clinic and CCCLMU of the University of Munich, Munich; Department of Gynecology, University Hospital Bonn, Bonn, Germany
| | - D Sattler
- Women's Clinic, Heinrich-Heine-University Duesseldorf, Duesseldorf; West German Study Group, Moenchengladbach; Breast Center Niederrhein, Ev. Bethesda Hospital, Moenchengladbach; Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen; Institute of Pathology, Hannover Medical School, Hannover; Institute of Pathology, University Clinics Erlangen, Erlangen; Trium Analysis Online GmbH, Munich; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg; Department of Obstetrics and Gynecology, Staedtisches Klinikum, Frankfurt; Clinics Deggendorf Mammacenter Ostbayern, Deggendorf; Breast Center, St Josephs-Hospital, Wiesbaden; Women's Clinic, Kreiskrankenhaus Boeblingen, Boeblingen; Department of Obstetrics and Gynecology, Ev. Hospital Oberhausen, Oberhausen; Breast Center, University Women's Clinic Ulm, Ulm; Department of Gynecology and Oncology, Dr. Horst-Schmidt-Klinik GmbH, Wiesbaden; Department of Gynecology and Obstetrics, Klinikum Rechts der Isar der Technischen Universität Muenchen (TUM), Munich; Breast Center, Women's Clinic and CCCLMU of the University of Munich, Munich; Department of Gynecology, University Hospital Bonn, Bonn, Germany
| | - C Thomssen
- Women's Clinic, Heinrich-Heine-University Duesseldorf, Duesseldorf; West German Study Group, Moenchengladbach; Breast Center Niederrhein, Ev. Bethesda Hospital, Moenchengladbach; Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen; Institute of Pathology, Hannover Medical School, Hannover; Institute of Pathology, University Clinics Erlangen, Erlangen; Trium Analysis Online GmbH, Munich; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg; Department of Obstetrics and Gynecology, Staedtisches Klinikum, Frankfurt; Clinics Deggendorf Mammacenter Ostbayern, Deggendorf; Breast Center, St Josephs-Hospital, Wiesbaden; Women's Clinic, Kreiskrankenhaus Boeblingen, Boeblingen; Department of Obstetrics and Gynecology, Ev. Hospital Oberhausen, Oberhausen; Breast Center, University Women's Clinic Ulm, Ulm; Department of Gynecology and Oncology, Dr. Horst-Schmidt-Klinik GmbH, Wiesbaden; Department of Gynecology and Obstetrics, Klinikum Rechts der Isar der Technischen Universität Muenchen (TUM), Munich; Breast Center, Women's Clinic and CCCLMU of the University of Munich, Munich; Department of Gynecology, University Hospital Bonn, Bonn, Germany
| | - M Kiechle
- Women's Clinic, Heinrich-Heine-University Duesseldorf, Duesseldorf; West German Study Group, Moenchengladbach; Breast Center Niederrhein, Ev. Bethesda Hospital, Moenchengladbach; Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen; Institute of Pathology, Hannover Medical School, Hannover; Institute of Pathology, University Clinics Erlangen, Erlangen; Trium Analysis Online GmbH, Munich; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg; Department of Obstetrics and Gynecology, Staedtisches Klinikum, Frankfurt; Clinics Deggendorf Mammacenter Ostbayern, Deggendorf; Breast Center, St Josephs-Hospital, Wiesbaden; Women's Clinic, Kreiskrankenhaus Boeblingen, Boeblingen; Department of Obstetrics and Gynecology, Ev. Hospital Oberhausen, Oberhausen; Breast Center, University Women's Clinic Ulm, Ulm; Department of Gynecology and Oncology, Dr. Horst-Schmidt-Klinik GmbH, Wiesbaden; Department of Gynecology and Obstetrics, Klinikum Rechts der Isar der Technischen Universität Muenchen (TUM), Munich; Breast Center, Women's Clinic and CCCLMU of the University of Munich, Munich; Department of Gynecology, University Hospital Bonn, Bonn, Germany
| | - F Jänicke
- Women's Clinic, Heinrich-Heine-University Duesseldorf, Duesseldorf; West German Study Group, Moenchengladbach; Breast Center Niederrhein, Ev. Bethesda Hospital, Moenchengladbach; Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen; Institute of Pathology, Hannover Medical School, Hannover; Institute of Pathology, University Clinics Erlangen, Erlangen; Trium Analysis Online GmbH, Munich; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg; Department of Obstetrics and Gynecology, Staedtisches Klinikum, Frankfurt; Clinics Deggendorf Mammacenter Ostbayern, Deggendorf; Breast Center, St Josephs-Hospital, Wiesbaden; Women's Clinic, Kreiskrankenhaus Boeblingen, Boeblingen; Department of Obstetrics and Gynecology, Ev. Hospital Oberhausen, Oberhausen; Breast Center, University Women's Clinic Ulm, Ulm; Department of Gynecology and Oncology, Dr. Horst-Schmidt-Klinik GmbH, Wiesbaden; Department of Gynecology and Obstetrics, Klinikum Rechts der Isar der Technischen Universität Muenchen (TUM), Munich; Breast Center, Women's Clinic and CCCLMU of the University of Munich, Munich; Department of Gynecology, University Hospital Bonn, Bonn, Germany
| | - D Wallwiener
- Women's Clinic, Heinrich-Heine-University Duesseldorf, Duesseldorf; West German Study Group, Moenchengladbach; Breast Center Niederrhein, Ev. Bethesda Hospital, Moenchengladbach; Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen; Institute of Pathology, Hannover Medical School, Hannover; Institute of Pathology, University Clinics Erlangen, Erlangen; Trium Analysis Online GmbH, Munich; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg; Department of Obstetrics and Gynecology, Staedtisches Klinikum, Frankfurt; Clinics Deggendorf Mammacenter Ostbayern, Deggendorf; Breast Center, St Josephs-Hospital, Wiesbaden; Women's Clinic, Kreiskrankenhaus Boeblingen, Boeblingen; Department of Obstetrics and Gynecology, Ev. Hospital Oberhausen, Oberhausen; Breast Center, University Women's Clinic Ulm, Ulm; Department of Gynecology and Oncology, Dr. Horst-Schmidt-Klinik GmbH, Wiesbaden; Department of Gynecology and Obstetrics, Klinikum Rechts der Isar der Technischen Universität Muenchen (TUM), Munich; Breast Center, Women's Clinic and CCCLMU of the University of Munich, Munich; Department of Gynecology, University Hospital Bonn, Bonn, Germany
| | - N Harbeck
- Women's Clinic, Heinrich-Heine-University Duesseldorf, Duesseldorf; West German Study Group, Moenchengladbach; Breast Center Niederrhein, Ev. Bethesda Hospital, Moenchengladbach; Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen; Institute of Pathology, Hannover Medical School, Hannover; Institute of Pathology, University Clinics Erlangen, Erlangen; Trium Analysis Online GmbH, Munich; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg; Department of Obstetrics and Gynecology, Staedtisches Klinikum, Frankfurt; Clinics Deggendorf Mammacenter Ostbayern, Deggendorf; Breast Center, St Josephs-Hospital, Wiesbaden; Women's Clinic, Kreiskrankenhaus Boeblingen, Boeblingen; Department of Obstetrics and Gynecology, Ev. Hospital Oberhausen, Oberhausen; Breast Center, University Women's Clinic Ulm, Ulm; Department of Gynecology and Oncology, Dr. Horst-Schmidt-Klinik GmbH, Wiesbaden; Department of Gynecology and Obstetrics, Klinikum Rechts der Isar der Technischen Universität Muenchen (TUM), Munich; Breast Center, Women's Clinic and CCCLMU of the University of Munich, Munich; Department of Gynecology, University Hospital Bonn, Bonn, Germany
| | - W Kuhn
- Women's Clinic, Heinrich-Heine-University Duesseldorf, Duesseldorf; West German Study Group, Moenchengladbach; Breast Center Niederrhein, Ev. Bethesda Hospital, Moenchengladbach; Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen; Institute of Pathology, Hannover Medical School, Hannover; Institute of Pathology, University Clinics Erlangen, Erlangen; Trium Analysis Online GmbH, Munich; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg; Department of Obstetrics and Gynecology, Staedtisches Klinikum, Frankfurt; Clinics Deggendorf Mammacenter Ostbayern, Deggendorf; Breast Center, St Josephs-Hospital, Wiesbaden; Women's Clinic, Kreiskrankenhaus Boeblingen, Boeblingen; Department of Obstetrics and Gynecology, Ev. Hospital Oberhausen, Oberhausen; Breast Center, University Women's Clinic Ulm, Ulm; Department of Gynecology and Oncology, Dr. Horst-Schmidt-Klinik GmbH, Wiesbaden; Department of Gynecology and Obstetrics, Klinikum Rechts der Isar der Technischen Universität Muenchen (TUM), Munich; Breast Center, Women's Clinic and CCCLMU of the University of Munich, Munich; Department of Gynecology, University Hospital Bonn, Bonn, Germany
| |
Collapse
|
35
|
van Dam P, Tomatis M, Marotti L, Heil J, Mansel R, Rosselli del Turco M, van Dam P, Casella D, Bassani L, Danei M, Denk A, Egle D, Emons G, Friedrichs K, Harbeck N, Kiechle M, Kimmig R, Koehler U, Kuemmel S, Maass N, Mayr C, Prové A, Rageth C, Regolo L, Lorenz-Salehi F, Sarlos D, Singer C, Sohn C, Staelens G, Tinterri C, Audisio R, Ponti A, Badbanchi F, Catalano G, Cretella E, Daniaux M, Emons A, van Eygen K, Ettl J, Gatzemeier W, Kern P, Schneeweiss A, Stoeblen F, Van As A, Wuerstlein R, Zanini V. Time trends (2006–2015) of quality indicators in EUSOMA-certified breast centres. Eur J Cancer 2017; 85:15-22. [DOI: 10.1016/j.ejca.2017.07.040] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2016] [Revised: 05/31/2017] [Accepted: 07/25/2017] [Indexed: 12/21/2022]
|
36
|
Windmüller C, Zech D, Avril S, Boxberg M, Dawidek T, Schmalfeldt B, Schmitt M, Kiechle M, Bronger H. CXCR3 mediates ascites-directed tumor cell migration and predicts poor outcome in ovarian cancer patients. Oncogenesis 2017; 6:e331. [PMID: 28504691 PMCID: PMC5523062 DOI: 10.1038/oncsis.2017.29] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2017] [Revised: 03/16/2017] [Accepted: 03/27/2017] [Indexed: 02/07/2023] Open
Abstract
Intraabdominal tumor dissemination is a major hallmark of epithelial ovarian cancer (EOC), but the underlying mechanisms have not been fully elucidated. The CXCR3 chemokine receptor supports migration of tumor cells to metastatic sites, but its role in ovarian cancer metastasis is largely unknown. Herein, we first screened two independent cohorts of high-grade serous ovarian cancers (HGSCs, discovery set n=60, validation set n=117) and 102 metastatic lesions for CXCR3 expression. In primary tumors, CXCR3 was particularly overexpressed by tumor cells at the invasive front. In intraabdominal metastases, tumor cells revealed a strong CXCR3 expression regardless of its expression in the corresponding primary tumor, suggesting a selection of CXCR3-overexpressing cancer cells into peritoneal niches. In support of this, CXCR3 mediated the migration of tumor cell lines OVCAR3 and SKOV3 toward malignant ascites, which was inhibited by a monoclonal anti-CXCR3 antibody in vitro. These results were prospectively validated in ascites-derived tumor cells from EOC patients ex vivo (n=9). Moreover, tumor cell-associated overexpression of CXCR3 in advanced ovarian cancer patients was associated with a reduced progression-free survival (PFS) and overall survival (OS), which remained independent of optimal debulking, age, FIGO stage and lymph node involvement (PFS: hazard ratio (HR) 2.11, 95% confidence interval (CI) 1.30–3.45, P=0.003; OS: HR 2.36, 95% CI 1.50–3.71, P<0.001). These results in ovarian cancer patients identify CXCR3 as a potential new target to confine peritoneal spread in ovarian cancer after primary cytoreductive surgery.
Collapse
Affiliation(s)
- C Windmüller
- Department of Gynecology and Obstetrics, Technical University of Munich, Munich, Germany
| | - D Zech
- Department of Gynecology and Obstetrics, Technical University of Munich, Munich, Germany
| | - S Avril
- Department of Pathology, Technical University of Munich, Munich, Germany
| | - M Boxberg
- Department of Pathology, Technical University of Munich, Munich, Germany
| | - T Dawidek
- Department of Gynecology and Obstetrics, Technical University of Munich, Munich, Germany.,Department of Pathology, Technical University of Munich, Munich, Germany
| | - B Schmalfeldt
- Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - M Schmitt
- Department of Gynecology and Obstetrics, Technical University of Munich, Munich, Germany
| | - M Kiechle
- Department of Gynecology and Obstetrics, Technical University of Munich, Munich, Germany
| | - H Bronger
- Department of Gynecology and Obstetrics, Technical University of Munich, Munich, Germany
| |
Collapse
|
37
|
Dietmaier T, Nest A, Hapfelmeier A, Große-Lackmann K, Kiechle M, Paepke D. Auswertung des FBK-R10 Fragebogens zur aktuellen Belastungssituation und Bedarf an psychoonkologischer Beratung bei Patientinnen mit Mammakarzinom. Geburtshilfe Frauenheilkd 2017. [DOI: 10.1055/s-0037-1602351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Affiliation(s)
- T Dietmaier
- Klinik und Poliklinik für Frauenheilkunde der Technischen Universität München
| | - A Nest
- Klinik und Poliklinik für Frauenheilkunde der Technischen Universität München
| | - A Hapfelmeier
- Klinik und Poliklinik für Frauenheilkunde der Technischen Universität München
| | - K Große-Lackmann
- Klinik und Poliklinik für Frauenheilkunde der Technischen Universität München
| | - M Kiechle
- Klinik und Poliklinik für Frauenheilkunde der Technischen Universität München
| | - D Paepke
- Klinik und Poliklinik für Frauenheilkunde der Technischen Universität München
| |
Collapse
|
38
|
Rottmann M, Burges A, Mahner S, Anthuber C, Beck T, Grab D, Schnelzer A, Kiechle M, Mayr D, Pölcher M, Schubert-Fritschle G, Engel J. Cancer of the ovary, fallopian tube, and peritoneum: a population-based comparison of the prognostic factors and outcomes. J Cancer Res Clin Oncol 2017; 143:1833-1844. [DOI: 10.1007/s00432-017-2422-6] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2016] [Accepted: 04/11/2017] [Indexed: 12/26/2022]
|
39
|
Dietmaier T, Nest A, Hapfelmeier A, Große Lackmann K, Kiechle M, Paepke D. Evaluation of psychological distress with the FBK-R10 survey in breast cancer patients. Breast 2017. [DOI: 10.1016/s0960-9776(17)30185-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
40
|
Welz B, Hapfelmeier A, Kiechle M, Paepke D. Retrospective analysis of utilization, compliance, tolerability and quality of life of breast cancer patients under complementary treatment (CAM). Breast 2017. [DOI: 10.1016/s0960-9776(17)30410-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
41
|
Dorn J, Yang F, Aubele M, Kiechle M, Schmitt M. Abstract P2-05-32: Tissue kallikrein-related peptidase 4, a novel biomarker in triple-negative breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-05-32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Triple-negative breast cancer (TNBC), lacking the steroid hormone receptors estrogen receptor and progesterone receptor and not overexpressing the oncoprotein HER2, is characterized by its aggressive pattern and insensitivity to endocrine and HER2-directed therapy. Human kallikrein-related peptidases KLK1-15 provide a rich source of serine protease-type biomarkers associated with tumor growth and cancer progression for a variety of malignant diseases. In this study, recombinant KLK4 protein was generated and affinity-purified KLK4-directed polyclonal antibody pAb587 established to allow localization of KLK4 protein expression in tumor cell lines and archived formalin-fixed, paraffin-embedded triple-negative breast cancer (TNBC) tumor tissue specimens. For this, KLK4 protein expression was assessed by immunohistochemistry in primary tumor tissue sections (tissue microarrays) of 188 TNBC patients, mainly treated with anthracycline- or CMF-based polychemotherapy. KLK4 protein is localized in the cytoplasm of tumor cells and that of accessory stroma cells. In this patient cohort, elevated stroma KLK4 expression, but not tumor cell expression, is predictive for poor disease-free survival by univariate analysis (hazard ratio: 2.26, p=0.001) and multivariable analysis (hazard ratio: 2.12, p<0.01). Likewise, univariate analysis revealed a trend for statistical significance of elevated KLK4 stroma cell expression for overall survival of TNBC patients as well.
Citation Format: Dorn J, Yang F, Aubele M, Kiechle M, Schmitt M. Tissue kallikrein-related peptidase 4, a novel biomarker in triple-negative breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-05-32.
Collapse
Affiliation(s)
- J Dorn
- Klinikum rechts der Isar, Munich, Germany; Institute of Pathology, Helmholtz Center Munich, Neuherberg, Germany
| | - F Yang
- Klinikum rechts der Isar, Munich, Germany; Institute of Pathology, Helmholtz Center Munich, Neuherberg, Germany
| | - M Aubele
- Klinikum rechts der Isar, Munich, Germany; Institute of Pathology, Helmholtz Center Munich, Neuherberg, Germany
| | - M Kiechle
- Klinikum rechts der Isar, Munich, Germany; Institute of Pathology, Helmholtz Center Munich, Neuherberg, Germany
| | - M Schmitt
- Klinikum rechts der Isar, Munich, Germany; Institute of Pathology, Helmholtz Center Munich, Neuherberg, Germany
| |
Collapse
|
42
|
Stassek J, Erdmann J, Ohnolz F, Berg FD, Kiechle M, Seifert-Klauss V. C-Peptide, Baseline and Postprandial Insulin Resistance after a Carbohydrate-Rich Test Meal - Evidence for an Increased Insulin Clearance in PCOS Patients? Geburtshilfe Frauenheilkd 2017; 77:59-65. [PMID: 28190890 DOI: 10.1055/s-0042-119199] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
Introduction Known characteristics of patients with PCOS include infertility, menstrual disorders, hirsutism and also often insulin resistance. These symptoms increase with increasing body weight. In the LIPCOS study (Lifestyle Intervention for Patients with Polycystic Ovary Syndrome [PCOS]) long-term changes of the PCOS in dependence on pregnancy and parenthood were systematically assessed. In the framework of the LIPCOS study, PCOS patients were given a standardised carbohydrate-rich test meal in order to examine glucose homeostasis and insulin secretion. The results were compared with those of a eumenorrhoeic control group who all had corresponding BMI values and corresponding ages. Methods and Patients 41 PCOS patients (without diabetes) and 68 controls received a standardised carbohydrate-rich test meal (260 kcal, 62 % carbohydrates, 32 % fat, 6 % proteins) in order to generate a submaximal insulin and glucose stimulation. The values were determined at baseline and postprandial after 60, 120 and 180 minutes. In addition, the corresponding C-peptide levels were recorded. Results In the PCOS patients (n = 41), the insulin secretion test after a standardised test meal showed almost identical baseline and postprandial insulin levels when compared with those of the age- and BMI-matched eumenorrhoeic controls (n = 68). In the PCOS patients, the baseline and postprandial glucose levels were significantly elevated (92.88 ± 10.28 [PCOS] vs. 85.07 ± 9.42 mg/dL [controls]; p < 0.001) so was C-peptide (p < 0.025). Conclusions In the present study we have shown for the first time that, after consumption of a standardised test meal, PCOS patients formally exhibit a higher fasting insulin resistance than controls. In spite of the higher stimulated C-peptide levels, the insulin levels did not increase more strongly with increasing glucose levels than in controls which may be indicative of a higher insulin clearance in PCOS patients.
Collapse
Affiliation(s)
- J Stassek
- Frauenklinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, München, Germany
| | - J Erdmann
- Hochschule Weihenstephan-Triesdorf, Weidenbach, Germany
| | - F Ohnolz
- Frauenklinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, München, Germany
| | - F D Berg
- Gemeinschaftspraxis Prof. Berg und Dr. Lesoine, München, Germany
| | - M Kiechle
- Frauenklinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, München, Germany
| | - V Seifert-Klauss
- Frauenklinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, München, Germany
| |
Collapse
|
43
|
Hederich P, Hapfelmeier A, Metz S, Kiechle M, Schmalfeldt B, Bronger H. Die prognostische Bedeutung von Sarkopenie beim fortgeschrittenen Ovarialkarzinom. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
44
|
Paepke S, Klein E, Kiechle M, Ankel C, Faridi A, Schumacher C, Meiré A, Blohmer JU, Mau C, Untch M, Ohlinger R, Strittmatter HJ, Thill M. Results of an pre-planned interim analysis of a national multicenter Patient Reported Outcome Study (PRO-Bra) in breast reconstruction with titaniferously coated polypropylene mesh (TiloopBra). Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1593149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
45
|
Bronger H, Windmüller C, Avril S, Dawidek T, Schmalfeldt B, Schmitt M, Kiechle M. Die Bedeutung des CXCR3-Chemokinrezeptors für die Peritonealmetastasierung des Ovarialkarzinoms. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1593266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
46
|
Dreyer T, Jelsma J, Schilling D, Multhoff G, Kiechle M, Bronger H. Das Chemokin CX3CL1 verbessert die Lyse von HER2-positiven Mammakarzinomzellen durch Natürliche Killerzellen. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
47
|
Konrad S, Schwamborn K, Hellmann D, Schmalfeldt B, Kiechle M, Meindl A, Ramser J. Identification and characterization of a specific neuronal calcium sensor protein as novel prognostic and predictive biomarker for ovarian cancer therapy. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
48
|
Schmidt G, Stassek J, Grill S, Munte A, Neumair R, Kotzur F, Kiechle M, Ettl J. Kombinationstherapie aus Trastuzumab Emtansin (T-DM 1) und Capecitabin bei HER2neu positivem metastasiertem Mammakarzinom – ein Fallbericht. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1593318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
49
|
Riedel J, Straub L, Wissing J, Artmann A, Schmidmayr M, Kiechle M, Seifert-Klauss VR. Vitamin D and Mammographic Findings. Geburtshilfe Frauenheilkd 2016; 76:570-578. [PMID: 27239067 DOI: 10.1055/s-0042-106208] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Introduction: Pleiotropic immune-modulatory and anti-proliferative effects of vitamin D and hopes to stop cancerogenesis have led to an increased interest in possible reduction of breast cancer with higher vitamin D levels. Mammographic density is an established risk factor for breast cancer risk, and its association with serum vitamin D is complex, as recent studies have shown. Patients and Methods: In this cross-sectional study, 1103 participants were recruited in the breast diagnostic unit of the Klinikum rechts der Isar, TU Munich. A standardised questionnaire and blood samples for 25-OH-vitamin D were taken on the day of mammography. Histologic results of biopsies in suspicious mammographies were documented. Results: In the 1090 data-sets analysed, vitamin D-deficiency was common among women under 40. Highest vitamin D values were observed in participants aged 60-69 years, but average values for all age cohorts were below 20 ng/ml of vitamin D. 15.6 % of all participants had very low vitamin D values (< 10 ng/ml), 51.3 % were vitamin D-deficient (10-19 ng/ml) and only 5.7 % were above 30 ng/ml, i.e. showed sufficient vitamin D. Patients with malignant results had vitamin D < 10 ng/ml more often (16.9 %; p = 0.61), and only 3.4 % in this group had sufficient vitamin D supply (> 30 ng/ml). There were no significant differences in vitamin D-levels between density groups according to the American College of Radiology (ACR) criteria. Conclusion: Vitamin D values were lower than in comparable US women. Up to now, there is no direct clinical evidence for a relationship between the risk for breast cancer and a specific vitamin D value.
Collapse
Affiliation(s)
- J Riedel
- Frauen- und Poliklinik der TU München, Munich
| | - L Straub
- Frauen- und Poliklinik der TU München, Munich
| | - J Wissing
- Frauen- und Poliklinik der TU München, Munich
| | | | | | - M Kiechle
- Frauen- und Poliklinik der TU München, Munich
| | | |
Collapse
|
50
|
Ioannou I, Utpadel-Fischler D, Tölle TR, Kiechle M, Ettl J. Erfassung der Chemotherapie-induzierten peripheren Neuropathie bei Mammakarzinom – Patientinnen mit taxanhaltiger Chemotherapie. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1580674] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|